# Postpartum Hemorrhage Treatment Sequence

Treat postpartum hemorrhage as simultaneous resuscitation and source control: quantify loss, assess tone, trauma, tissue, and thrombin, give early tranexamic acid, escalate rapidly from uterotonics to tamponade or operative control, and replace fibrinogen before severe coagulopathy develops.

**Clinical question:** What is the practical treatment sequence for postpartum hemorrhage from recognition through definitive hemorrhage control?

Updated: 2026-09-15T21:38:34.719482+00:00

## What matters in practice
- Do not wait for a fixed blood-loss threshold when bleeding is abnormal or hemodynamic signs appear; cumulative blood loss of at least 1,000 mL with hypovolemia within 24 hours meets the contemporary PPH definition. [20]
- Activate parallel hemorrhage management: quantify loss, obtain CBC, platelet count, coagulation studies, and fibrinogen, establish resuscitation access, and identify the bleeding source using the 4 Ts. [18][20]
- Give intravenous tranexamic acid as soon as PPH is diagnosed and within 3 hours of birth, in addition to standard care. [13]
- For uterine atony, proceed from uterine massage and oxytocin to a nonredundant uterotonic; carboprost is 250 micrograms IM every 15-30 minutes when appropriate, with asthma as a relative contraindication. [7]
- Ongoing severe bleeding requires early mechanical or operative source control rather than serial medication trials: intrauterine balloon tamponade, compression sutures, uterine devascularization or embolization, then hysterectomy when bleeding remains uncontrolled. [6][8]
- Check fibrinogen early in severe PPH; a level below 2 g/L predicts progression to severe bleeding and warrants fibrinogen replacement, with a target of at least 150-200 mg/dL during massive transfusion. [21][22]

## Recognize abnormal bleeding and activate the hemorrhage response

Management begins before conventional volume criteria are reached when bleeding is clinically concerning.

Use quantitative blood-loss measurement rather than visual estimation, and treat continued abnormal bleeding with any hemodynamic deterioration as an obstetric emergency. A cumulative blood loss of 1,000 mL or more accompanied by signs or symptoms of hypovolemia within 24 hours after birth defines PPH regardless of delivery route; primary PPH occurs within 24 hours, whereas secondary PPH occurs from 24 hours to 6-12 weeks postpartum. [1][20]

At recognition, call obstetric anesthesia, the blood bank, and senior obstetric support; establish resuscitation and initiate the institutional massive-transfusion pathway if bleeding is rapid or ongoing. Care bundles using quantitative measurement, senior escalation at 1,000 mL and 1,500 mL, point-of-care hemostasis testing at 1,000 mL or more, and early tranexamic acid were associated with less progression to severe PPH of at least 2,500 mL and fewer transfusions. [18]

Obtain a CBC with platelet count, fibrinogen, and coagulation testing while treatment proceeds; do not defer source control pending results. In severe ongoing PPH, standard fibrinogen testing or viscoelastic testing with ROTEM or TEG provides earlier actionable assessment of hypofibrinogenemia than waiting for later clinical coagulopathy. [19][20][21]
- Document quantified cumulative loss and reassess uterine tone, vaginal/perineal bleeding, and hemodynamics after every intervention. [18][20]
- Warm the patient and monitor acid-base status and calcium during major transfusion because citrate-related hypocalcemia can impair coagulation and uterine contraction. [21]
- Use point-of-care coagulation testing only where trained staff and quality-control processes are available. [19]

*Escalation triggers for immediate postpartum hemorrhage response. [18][20]*

| Finding | Interpretation | Immediate next action |
| --- | --- | --- |
| Abnormal postpartum bleeding with hemodynamic signs | Treat as clinically significant hemorrhage even before 1,000 mL cumulative loss. [20][24] | Activate PPH response; begin source assessment and resuscitation simultaneously. [20] |
| Cumulative blood loss at least 1,000 mL | Threshold for senior escalation and point-of-care hemostasis assessment in a structured bundle. [18] | Escalate to senior clinicians, obtain fibrinogen/coagulation assessment, and prepare blood products. [18][21] |
| Cumulative blood loss at least 1,500 mL or rapidly ongoing bleeding | High-risk trajectory requiring intensified multidisciplinary response. [18] | Activate or intensify massive-transfusion and definitive hemorrhage-control planning. [18][21] |
| Fibrinogen below 2 g/L | Early predictor of progression to severe bleeding. [21] | Replace fibrinogen with cryoprecipitate or fibrinogen concentrate according to local protocol. [21][22] |

## Use the 4 Ts to choose source-directed treatment

Atony is common, but persistent bleeding despite a firm uterus requires immediate source reassessment.

Perform a focused 4 Ts assessment during resuscitation: Tone (uterine atony), Trauma (laceration, hematoma, uterine rupture or inversion), Tissue (retained products or abnormal placentation), and Thrombin (acquired or inherited coagulopathy). Uterine atony is the most common cause of primary PPH, but trauma, retained tissue, and coagulopathy require fundamentally different interventions. [20][14][15]

A boggy, enlarged uterus supports atony and warrants uterine massage, bimanual compression, and uterotonics. Continued brisk bleeding with a firm contracted uterus should prompt inspection for cervical, vaginal, perineal, or operative-site trauma; assess for concealed puerperal genital hematoma when pain, pressure, or hemodynamic compromise exceeds visible blood loss. [8][15]

If placental delivery is incomplete, bleeding persists with suspected retained tissue, or delayed hemorrhage develops, evaluate for retained or residual products of conception. Secondary hemorrhage is commonly associated with retained products, infection, subinvolution of the placental site, lacerations, uterine atony, and inherited coagulation disorders; pelvic imaging can help define retained products, hematoma, uterine dehiscence, or other structural causes. [1][14][15]
- Tone: massage, bimanual compression, uterotonics, then tamponade or operative uterine compression when bleeding persists. [7][8]
- Trauma: expose and repair lacerations; do not expect uterotonics to control bleeding from a genital tract injury. [15]
- Tissue: remove retained tissue when identified and plan early multidisciplinary hemorrhage control for placenta accreta spectrum or placenta previa-associated bleeding. [5][14]
- Thrombin: obtain fibrinogen, platelet count, and coagulation studies early; replace deficits while treating the anatomic source. [20][21][22]

*Etiologic branch points that change postpartum hemorrhage treatment. [8][14][15][20]*

| Branch | Bedside discriminator | Treatment direction |
| --- | --- | --- |
| Tone | Boggy or poorly contracted uterus. [20] | Uterine massage and bimanual compression; administer uterotonics; escalate promptly to balloon tamponade or uterine compression procedures if refractory. [7][8] |
| Trauma | Persistent bleeding despite a firm uterus; visible laceration or suspected hematoma. [15] | Identify and repair the injury; evaluate structural complications such as rupture or dehiscence when indicated. [15] |
| Tissue | Incomplete placenta, suspected retained products, or bleeding associated with abnormal placentation. [1][14] | Address retained tissue and use multidisciplinary operative planning for placenta accreta spectrum or placenta previa-associated hemorrhage. [5][14] |
| Thrombin | Low fibrinogen, thrombocytopenia, abnormal coagulation testing, or bleeding disproportionate to local findings. [20][21] | Deliver targeted blood-component therapy while continuing mechanical or surgical hemostasis. [21][22] |

## Treat uterine atony with simultaneous antifibrinolytic therapy and uterotonics

Medication should occur while the uterus is assessed and mechanical escalation is prepared.

For suspected atony, begin uterine massage and bimanual compression with oxytocin-based uterotonic treatment. If bleeding continues, select an additional uterotonic with a different mechanism rather than repeating ineffective treatment; the choice depends on contraindications and the clinical speed of hemorrhage. [7][8]

Administer intravenous tranexamic acid as soon as PPH is diagnosed and within 3 hours after birth, as an adjunct to standard PPH treatment rather than as a substitute for uterotonics, repair, tamponade, transfusion, or surgery. In structured treatment bundles, tranexamic acid was given upon recognition of abnormal bleeding and repeated if bleeding continued. [13][18]

Carboprost is a practical second-line uterotonic for refractory atony after uterine massage and oxytocin when methylergonovine is ineffective or contraindicated. Give 250 micrograms intramuscularly and repeat every 15-30 minutes as needed; avoid or use exceptional caution in asthma because bronchospasm risk makes asthma a relative contraindication. [7]
- Do not continue a medication-only sequence when bleeding remains brisk after initial uterotonic treatment; move to tamponade or operative control while blood products are mobilized. [6][8]
- Use clinical response—uterine tone and bleeding rate—not elapsed time alone—to determine whether atony treatment has failed. [7][8]
- When a nonatony source is identified, direct treatment to that source even if uterotonics have already been administered. [8][15]

*Medication choices supported for the early atony branch. [7][13][18]*

| Intervention | When to use | Dose or timing | Key limitation |
| --- | --- | --- | --- |
| Uterine massage and bimanual compression | Immediate intervention for suspected uterine atony. [7][8] | Initiate immediately while uterotonics and source assessment proceed. [7][8] | Insufficient alone in refractory hemorrhage. [8] |
| Oxytocin | First-line medication used with uterine massage for atony. [7] | Use per institutional obstetric hemorrhage protocol; a dose was not specified in the cited material. [7] | Persistent bleeding requires an additional uterotonic or mechanical escalation. [7][8] |
| Tranexamic acid | Adjunct once PPH is diagnosed. [13] | Intravenous administration as soon as diagnosed and within 3 hours of birth. [13] | Does not replace anatomic source control. [13][18] |
| Carboprost | Refractory atony after massage and oxytocin, especially when methylergonovine is ineffective or unsuitable. [7] | 250 micrograms IM; repeat every 15-30 minutes as needed. [7] | Asthma is a relative contraindication. [7] |

## Escalate rapidly from tamponade to vascular control or hysterectomy

Persistent hemorrhage after initial medical therapy is an indication for procedural control, not prolonged observation.

For refractory uterine bleeding after uterotonics, use intrauterine balloon tamponade as an early uterus-preserving mechanical option when the uterus is the likely bleeding source. Failure of tamponade, uncontrolled bleeding, or concern for a surgical source should prompt operative escalation without delay. [6][8]

Uterus-preserving operative options include uterine compression sutures such as B-Lynch, Hayman, or Cho techniques; uterine artery ligation; stepwise uterine devascularization; internal iliac artery ligation; and selective arterial embolization. Selection depends on delivery route, bleeding site and volume, hemodynamic tolerance, and immediate technical and personnel availability. [6][8]

Arterial embolization can preserve reproductive function but requires a stable enough patient, immediate interventional radiology capability, and no delay in control of exsanguinating hemorrhage. High-risk patients, particularly those with placenta accreta spectrum or placenta previa, should be managed at centers with 24-hour multidisciplinary and interventional radiology resources when feasible. [5][6]

Proceed to peripartum hysterectomy when conservative medical, mechanical, and vascular-control measures cannot achieve hemostasis or when the clinical situation makes fertility-preserving approaches unsafe. In a tertiary-center series of PPH requiring massive-transfusion protocol activation, 19% underwent peripartum hysterectomy and 61% required ICU admission, underscoring the need to avoid delayed escalation. [4]
- Use balloon tamponade as a therapeutic maneuver for uterine-source bleeding after failed uterotonics. [6][8]
- Choose compression sutures or uterine devascularization when laparotomy is already underway or immediate surgical control is required. [6][8]
- Choose uterine artery embolization when bleeding is ongoing but time, stability, and interventional radiology access permit transfer to angiography without compromising definitive control. [5][6]
- Do not defer hysterectomy for sequential conservative procedures in rapidly deteriorating or uncontrolled hemorrhage. [4][8]

*Procedure selection after failed initial uterotonic management. [5][6][8]*

| Procedure | Best-fit clinical circumstance | Practical tradeoff |
| --- | --- | --- |
| Intrauterine balloon tamponade | Refractory uterine bleeding when a uterus-preserving mechanical intervention is appropriate. [6][8] | Can avert laparotomy, but failure requires prompt progression to operative or vascular control. [6][8] |
| Uterine compression sutures | Persistent atony requiring operative management, particularly when laparotomy is available. [6][8] | May preserve fertility but requires surgical expertise and does not address unrecognized trauma or retained tissue. [6][8] |
| Uterine or internal iliac artery ligation / devascularization | Ongoing surgical hemorrhage requiring vascular reduction. [6][8] | Provides immediate operative control but requires technical expertise. [6][8] |
| Selective arterial embolization | Persistent hemorrhage in a patient for whom angiographic management can be performed without dangerous delay. [5][6] | Potentially fertility-preserving; dependent on interventional radiology access and patient stability. [5][6] |
| Peripartum hysterectomy | Uncontrolled life-threatening hemorrhage after failed conservative measures or when conservative treatment is unsafe. [4][8] | Definitive hemostasis at the cost of fertility. [4][8] |

## Replace blood components early and target fibrinogen during severe hemorrhage

Transfusion is supportive until source control is achieved; its purpose is to maintain oxygen delivery and correct evolving coagulopathy.

During severe ongoing PPH, monitor fibrinogen early because it is the first coagulation factor to fall to critical levels. A fibrinogen concentration below 2 g/L has been reported to predict progression to severe bleeding, and values below 200 mg/dL are an indication for component replacement; target at least 150-200 mg/dL during massive transfusion. [21][22]

Use cryoprecipitate or fibrinogen concentrate according to the institution's PPH protocol and product availability. A usual cryoprecipitate dose of 10 units is estimated to increase fibrinogen by approximately 100 mg/dL, but repeat laboratory or viscoelastic assessment should determine whether the target has been achieved. [22]

When hemorrhage is massive, activate a ratio-driven blood-product protocol rather than waiting for isolated laboratory abnormalities; published obstetric protocols use RBC:FFP:platelet ratios of 6:4:1, 4:4:1, or 1:1:1, although these ratios are extrapolated from trauma literature and no single obstetric ratio is established. [21]

In the nonmassively bleeding phase, a restrictive RBC transfusion threshold of hemoglobin below 7 g/dL is preferred. With active bleeding, RBC transfusion thresholds may shift to hemoglobin 7-9 g/dL depending on local protocol and maternal comorbidity; continue to correct hypothermia, acid-base derangement, and citrate-associated hypocalcemia during major transfusion. [21]
- Obtain fibrinogen early in severe PPH; do not rely on hemoglobin alone to detect impending coagulopathy. [21][22]
- Use ROTEM or TEG to guide targeted replacement when available and interpreted by trained clinicians. [19][21]
- Reassess bleeding source after each transfusion cycle; worsening laboratory values without source control require procedural escalation. [21]

*Laboratory-guided hemostatic decisions in severe postpartum hemorrhage. [21][22][23]*

| Parameter | Actionable result | Treatment implication |
| --- | --- | --- |
| Plasma fibrinogen | Below 2 g/L predicts progression to severe bleeding; below 200 mg/dL indicates component replacement. [21][22] | Give cryoprecipitate or fibrinogen concentrate and target at least 150-200 mg/dL. [22] |
| ROTEM FIBTEM A5 | A5 of 12 mm or less had a positive predictive value of 22.5% for progression to severe PPH. [23] | Use within a trained, protocolized viscoelastic-testing pathway to guide early fibrinogen-focused therapy. [19][23] |
| Hemoglobin during nonmassive bleeding | Below 7 g/dL. [21] | Use restrictive RBC transfusion strategy if not actively massively bleeding. [21] |
| Hemoglobin during active bleeding | 7-9 g/dL may be used depending on local protocol and maternal conditions. [21] | Transfuse in the context of active loss, physiology, and concurrent component replacement. [21] |

## Evaluate secondary postpartum hemorrhage for retained tissue, infection, or vascular injury

Bleeding beginning after the first 24 hours follows a different diagnostic branch than immediate atony.

For hemorrhage from 24 hours through 6-12 weeks postpartum, first reassess hemodynamic status and quantify active loss, then prioritize retained products of conception, infection, subinvolution of the placental site, laceration, uterine atony, and inherited coagulation disorders. This timing distinction matters because delayed bleeding should not be presumed to be uncomplicated uterine atony. [1][20]

Use pelvic imaging when the clinical assessment suggests retained products, genital tract hematoma, uterine rupture or dehiscence, or another structural source. Imaging is particularly useful when bleeding persists despite initial bedside assessment or when the source is not visible on examination. [14][15]

If secondary hemorrhage is hemodynamically significant, initiate the same resuscitation, blood-bank, and hemostatic pathway used for primary PPH while arranging source-directed treatment. Delayed presentation does not reduce the need for urgent fibrinogen assessment and procedural escalation when bleeding is severe. [1][21]
- Retained or residual products on clinical or imaging evaluation direct management toward uterine source control rather than repeated empiric uterotonics. [14][15]
- Pain or pressure with disproportionate shock should raise concern for a concealed genital tract hematoma. [15]
- Suspected coagulopathy warrants CBC, platelet count, coagulation testing, and fibrinogen assessment during active hemorrhage. [20][21]

*Secondary postpartum hemorrhage branch points. [1][14][15][20]*

| Pattern | Likely concern | Next step |
| --- | --- | --- |
| Bleeding 24 hours to 6-12 weeks after birth | Secondary PPH. [1][20] | Reassess hemodynamics and evaluate tissue, infection, trauma, and coagulation causes. [1][20] |
| Persistent bleeding with suspected intrauterine source | Retained or residual products of conception. [14][15] | Use pelvic imaging and arrange source-directed uterine management. [14][15] |
| Pain, pressure, or shock exceeding visible blood loss | Puerperal genital hematoma or other concealed trauma. [15] | Perform targeted examination and imaging for structural injury. [15] |
| Bleeding with abnormal hemostatic testing | Coagulopathy contributing to ongoing hemorrhage. [20][21] | Replace deficits, especially fibrinogen, while controlling the anatomic source. [21][22] |

## References
1. Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5 — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2021.02.033
2. Point-of-Care Fibrinogen Testing and Hemorrhage... — journals.lww.com — https://journals.lww.com/00060825-202609000-00009
3. Massive obstetric hemorrhage: Current approach to management - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2173572716300212
4. Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: a retrospective study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0959289X12000441
5. Prophylactic interventional radiological... : The Indian Anaesthetists Forum — journals.lww.com — https://journals.lww.com/iaaf/fulltext/2021/22010/prophylactic_interventional_radiological.3.aspx
6. Medical and Conservative Surgical Management of Postpartum Hemorrhage - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1701216316302419
7. Carboprost - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/carboprost
8. Management of intractable postpartum haemorrhage... : Nigerian Medical Journal — journals.lww.com — https://journals.lww.com/nimj/fulltext/2012/53020/management_of_intractable_postpartum_haemorrhage.6.aspx
9. Postpartum haemorrhage in high‐resource settings: Variations in clinical management and future research directions based on a comparative study of national guidelines - Vries - 2023 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17551
10. Tranexamic acid for preventing postpartum blood loss after ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.12798
11. The Use of Tranexamic Acid to Prevent Postpartum ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jmwh.13101
12. Women receiving massive transfusion due to postpartum ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.13542
13. FIGO recommendations on the management of postpartum ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116
14. Secondary Postpregnancy Hemorrhage: Guide for Diagnosis and ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/rg.240098
15. Imaging of Antepartum and Postpartum Hemorrhage - RSNA Journals — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/rg.230164
16. Imaging of Antepartum and Postpartum Hemorrhage — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.230164
17. Interventional Radiology and Pregnancy: From Conception ... — pubs.rsna.org — https://pubs.rsna.org/doi/pdf/10.1148/rg.230029
18. Evidence-to-decision framework: treatment bundles for postpartum haemorrhage - WHO recommendations on the assessment of postpartum blood loss and use of a treatment bundle for postpartum haemorrhage - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK598983
19. Haemostatic monitoring during postpartum haemorrhage and implications for management - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3498756
20. Postpartum Hemorrhage - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK499988
21. Management of Postpartum Haemorrhage — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9885818
22. FIGO recommendations on the management of postpartum ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9313855
23. Clinical value of early viscoelastometric point‐of‐care testing during ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8453832
24. Recommendations and supporting evidence - Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK619233

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.